[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brca12\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brca12":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100608143","study-of-how-people-make-decisions-about-prostate-cancer-risk-100608143",false,"NCT07197723","Study of How People Make Decisions About Prostate Cancer Risk","Effect of Polygenic Risk Modifiers on Decisions of BRCA1\u002F2 Mutation Carriers at Risk for Prostate Cancer","Inclusion Criteria:\n\n* Documentation of Disease\n\n  o Patients must not have prostate cancer (for individuals not presently receiving care at the study site, this information will be based on self-report.)\n* Age between 45 - 70;\n* Assigned male sex at birth for individuals not presently receiving care at the study site, this information will be based on self-report.)\n* Completed full sequence or targeted genetic testing with a result confirmed in a clinically approved laboratory showing a BRCA1\u002F2 likely pathogenic or pathogenic variant identified, or clinician note documents a BRCA1\u002F2 likely pathogenic or pathogenic variant\n* English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.(for individuals not presently receiving care at the study site, this information will be based on self-report.)\n\nExclusion Criteria:\n\n* Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.\n* Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.\n* Under active treatment for a malignancy. (Patients are eligible if they have a prior history of malignancy other than prostate cancer, as long as they are not currently undergoing active treatment for the malignancy) (for individuals not presently receiving care at the study site, this information will be based on self-report.)\n* Enrolled in NCI study 19-C-0040 (Natural History of Men at High-Risk for Prostate Cancer) based on self-report\n* Patients with a known pathogenic and\u002For likely pathogenic germline variant in any hereditary prostate cancer risk gene, excluding BRCA1 and\u002For BRCA2, including but not limited to: HOXB13, ATM, CHEK2, NBN, PALB2, MLH1, MSH2, MSH6, PMS2,RAD51C, RAD51D and TP53.\n* Any patient who has had a prostate biopsy within 36 months, according to clinician note (for individuals not presently receiving care at the study site, this information will be based on self-report)","MALE","45 Years","70 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to learn how people with BRCA1\u002F2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.",[25,26],"BRCA1\u002F2","Geneitic Testing",[28,29,30],"Polygenic Risk Modifiers","BRCA1\u002F2 Mutation Carriers","Assessments","RECRUITING","2026-07-09",{"date":34,"type":35},"2026-07-10","ACTUAL",{"date":37,"type":35},"2025-09-25",{"date":39,"type":21},"2027-09",{"name":41,"class":42},"Memorial Sloan Kettering Cancer Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100316190","responses-to-genetic-risk-modifier-testing-among-women-with-pathogenic-variants-in-breast-cancer-predisposition-genes-100316190","NCT03396341","Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes","Inclusion Criteria:\n\nPhase I:\n\n* Female patient, age 25 years or older (given that women under this age are not generally recommended to receive BRCA1\u002F2 genetic testing)\n* Completed full sequence or targeted genetic testing with a clinically confirmed BRCA1 or BRCA2 deleterious mutation identified\n* No personal history of breast cancer\n* English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.\n\nPhase 2:\n\n* Female sex\n* Completed germline genetic testing with one clinically confirmed pathogenic\u002Flikely pathogenic variant in either of the following genes and with the associated age minimums:\n\n  * BRCA1 and currently age 25 years or older\n  * BRCA2 and currently age 25 years or older\n  * ATM (all pathogenic\u002Flikely pathogenic variants EXCEPT for the variant ATM c.7271T\\>G \\[p.Val2424Gly\\]) and currently age 30 years or older\n  * CHEK2 (all pathogenic\u002Flikely pathogenic variants EXCEPT for the variants CHEK2 c.470T\\>C \\[p.Ile157Thr ; I157T\\] and CHEK2 c.1283C\\>T\\[p.Ser428Phe ; p.S428F\\] and CHEK2 c.1427C\\>T \\[p.Thr476Met\\]) and currently age 30 years or older\n  * PALB2 and currently age 30 years or older\n* No personal history of breast cancer\n* English-fluent based on self-report or the EMR; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.\n\nExclusion Criteria:\n\nPhase I:\n\n* Previous receipt of any prophylactic mastectomy.\n* Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.\n* Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.\n\nPhase 2:\n\n* Previous receipt of any prophylactic mastectomy.\n* Major untreated psychiatric illness or cognitive impairment that would preclude study participation.\n* Any patients who participated and received genetic risk modifier test results from Phase 1 of this protocol.","FEMALE","25 Years",{"count":53,"type":21},806,"The purpose of this study is to describe how women with BRCA1\u002F2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.",[56,25],"Genetic Testing",[58,59],"BRCA1\u002F2 Mutations","17-489","2026-05-15",{"date":62,"type":35},"2026-05-19",{"date":64,"type":35},"2018-01-04",{"date":66,"type":21},"2027-01",{"name":41,"class":42},7]